Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank57
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-56.37M
↑ 15% vs avg
Percentile
P57
Within normal range
Streak
2 yr
Consecutive growthExpanding
Average
$-66.24M
Historical baseline
PeriodValueYoY Change
TTM$-56.37M+45.6%
2024$-103.65M+6.3%
2023$-110.58M-27.5%
2022$-86.75M-1.0%
2021$-85.85M-83.5%
2020$-46.80M-77.0%
2019$-26.45M-96.1%
2018$-13.48M-